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Aim: (5R)-5-Hydroxytriptolide (LLDT-8), an analogue of triptolide, displays lower toxicity compared to
triptolide and has comparable immunosuppressive effects. We investigated the anti-inﬂammatory and
neuroprotective effects of LLDT-8 on cerebral ischemia/reperfusion injury.
Methods: Nitric oxide production from microglia was assessed by measuring the nitrite concentration in
the culture medium with Griess reagent. Microglial cells and ischemic brain tissues were examined for
the expression of proinﬂammatory mediators by qPCR and western blot. Infarct volumes were assessed
with TTC histology. The TLR4/NF-kB signaling pathway was analyzed with western blot and
immunocytochemistry.
Results: LLDT-8 signiﬁcantly reduced infarct sizes and expression of pro-inﬂammatory cytokines in the
ischemic cortex. LLDT-8 inhibited NO release and expression of TNF-a, IL-1b and iNOS in BV-2 microglia
and primary microglia treated with LPS. In addition, LLDT-8 suppressed expression of TLR4, degradation
of IkBa and nuclear translocation of NF-kB.
Conclusion: LLDT-8 exerted anti-inﬂammatory effects and protected against acute cerebral ischemia/
reperfusion injury possibly by acting through the IkB/NF-kB cascade to suppress microglia-mediated
neuroinﬂammation.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Stroke is a disease that leads to disability and death, but un-
fortunately, effective stroke treatments are rather limited (1).
Sudden interruption of cerebral blood ﬂow triggers an inﬂamma-
tory response and consequently causes irreversible injury in thef Translational Research and
harmaceutical Sciences, Soo-
5123, PR China.
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d/4.0/).brain (2). Moreover, delayed restoration of blood and oxygen in the
brain parenchyma induces more robust inﬂammation and exacer-
bates ischemic injury (3).
Microglia are resident macrophages of the central nervous
system (CNS) and constantly monitor the brain environment under
normal physiological conditions (4). When brain ischemia occurs,
microglia shift to an inﬂammatory phenotype and accumulate at
the injury site and in the penumbra (5). Activated microglia
contribute to the ischemia inﬂammatory response by releasing pro-
inﬂammatory mediators, such as TNF-a, IL-1b, and NO. Suppressing
cerebral inﬂammation by the administration of antibodies to
neutralize TNF-a or IL-1b is protective in experimentally induced
stroke (6,7).
Tripterygium wilfordii Hook. f. (TWHF) is a Chinese traditional
herb that has been used to treat autoimmune diseases (8). Trip-
tolide, which is the most active component isolated from TWHF,nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Y. Chen et al. / Journal of Pharmacological Sciences 131 (2016) 131e137132exhibits strong immunosuppressive activity; however, the toxicity
of triptolide prevents its clinical application (9). (5R)-5-Hydroxy-
triptolide (LLDT-8) is synthesized as an analogue of triptolide.
LLDT-8 possesses immunosuppressive effects comparable to trip-
tolide and has a much lower toxicity (10). LLDT-8 has been re-
ported to reduce the production of NO and TNF-a in the LPS-
stimulated macrophage cell line Raw 264.7 by inhibiting the
DNA binding activity of NF-kB (11). However, whether LLDT-8
protects against cerebral ischemic injury by inhibiting neuro-
inﬂammation has not been investigated; therefore, we addressed
this question herein.2. Materials and methods
2.1. Animal model of transient focal ischemia
Male ICR mice weighing between 25 and 30 g were purchased
from SLAC Laboratory Animal (Shanghai, China). The animal
experimental procedures were performed in accordance with
institutional guidelines and approved by the Animal Care and Use
Committee of Soochow University. Middle cerebral artery occlusion
(MCAO) was induced in mice with a monoﬁlament technique as
previously described (12). Brieﬂy, adult mice were anesthetized
with isoﬂurane, and the right middle cerebral artery was occluded
by intraluminally inserting a nylon monoﬁlament using a tip that
was blunted with heat and coated with silicon resin. Occlusion was
sustained for 1 h, and then, blood ﬂow was restored by with-
drawing the ﬁlament. Sham operated mice underwent identical
surgical procedures without ﬁlament insertion. LLDT-8 was dis-
solved in dimethyl sulfoxide (sigma) at 30 mg/ml and diluted with
saline to a ﬁnal concentration of 0.15 mg/ml. Mice were adminis-
tered LLDT-8 (i.p.) immediately after reperfusion at the doses of
0.5 mg/kg or 1 mg/kg. The in vivo doses of LLDT-8 were determined
based on the previous publications (8,13,14).2.2. Assessment of brain infarct damage
Brain infarct volumes were evaluated by staining brain slices
with 2,3,5-triphenyltetrazolium chloride (TTC, Sigma). Twenty four
hours after reperfusion, brains were cut into four coronal slices
using a mouse brain matrix. The slices were stained with a 1% TTC
solution at 37 C for 10 min and then ﬁxed in 4% paraformaldehyde
for 24 h. Infarct sizes were analyzed using Image J. The results are
presented as the percentage of infarct volumes normalized to
contralateral structures.2.3. BV-2 cell culture
Mouse BV-2microglial cells were cultured at 37 C and 5% CO2 in
DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin.2.4. Primary microglial cultures
Mouse primary microglia were prepared from brain cortex tis-
sues of 1- to 2-day-old mouse pups as previously described (15).
Brieﬂy, cortical tissues were digested with 0.2% papain dissolved in
DMEM/F12. Dissociated cells were seeded onto T75 ﬂasks coated
with poly-D-lysine (PDL) and cultured in DMEM/F12 supplemented
with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin at
37 C and 5% CO2 for 14 days, replacing the culture medium every
3e4 days. Microglia were isolated from mixed glia by shaking the
ﬂasks for 90 min at 180 r.p.m.2.5. Real-time PCR
Total RNAwas extracted from cortical ischemic penumbra tissue,
BV-2 cells or primary microglia using RNAiso plus reagent (Takara)
per the manufacturer's instructions. Reverse transcription of 1 mg of
total RNA to cDNA was performed using a high-capacity cDNA
Reverse Transcription Kit (Applied Biosystems). qPCR reactionswere
performed in triplicate using the ABI Prism 7500 Real-time PCR
System.mRNA levelswere normalized to 18S rRNA. The sequences of
qPCR primers were as follows: TNF-a (forward primer: 50-
CATCTTCTCAAAATTCGAGTGACAA-30; reverse primer: 50-TGGGAGT
AGACAAGGTACAACCC-30); IL-1b (forward primer: 50-TGGAAAA
GCGGTTTGTCTTC-30; reverseprimer: 50-TACCAGTTGGGGAACTCTGC-
30); iNOS (forward primer: 50-CAGGAGGAGAGAGATCCGATTTA-30;
reverse primer: 50-GCATTAGCATGGAAGCAAAGA-30); 18S (forward
primer: 50-GTAACCCGT TGAACCCCATT-30; reverse primer: 50-
CCATCCAATCGGTAGTAGCG-30).
2.6. Assay of NO production
NO production by microglia was assessed by measuring the
nitrite concentrations in the culturing medium by the Griess test.
Brieﬂy, microglia were stimulated with or without LPS (100 ng/ml,
Sigma) for 24 h. Then, the supernatant was collected and mixed
with an identical volume of Griess reagent. The nitrite concentra-
tions were calculated from a standard curve that was generated by
serially diluted solutions of sodium nitrite (from 0 mM to 150 mM).
2.7. Cell viability assay
For MTT assays, cells were seeded onto 96-well plates at cell
densities of 5000 to 1,0000 cells per well. Cells were incubated at
37 C and 5% CO2. After treatments, the culture medium was
replaced with 30 ml of culture medium containing 0.5 mg/ml MTT.
The cells were incubated at 37 C for 2 h. Then, the medium was
discarded and 100 ml of DMSO was added to the wells to dissolve
the cells. After shaking the mixture, the absorbance was assayed at
570 nm.
2.8. Western blot analysis
The culture mediumwas discarded, and BV-2 cells were washed
twice with cold PBS. Cells were collected and lysed with lysis buffer
(150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate (SDS), 50mM Tris, pH 8.0, and protease
and phosphatase inhibitor cocktail) on ice for 30 min. The mixture
was centrifuged, and the supernatants were harvested. The protein
concentration of the supernatants was determined with a BCA
assay. Forty micrograms of protein from each sample was loaded
and resolved on 10% SDSePAGE gels and then transferred to PVDF
membranes. The membranes were blocked with 5% skim milk for
2 h at room temperature. Then, the membranes were incubated
with the following primary antibodies at 4 C overnight: phosphor-
IkBa (1:1000; Cell Signaling) iNOS (1:800, Abcam) and TLR4
(1:1000; Santa Cruz Biotechnology). After being washed with TBST,
themembraneswere incubatedwith an HRP-conjugated secondary
antibody for 2 h. The protein was detected with a chem-
iluminescence detection system.
2.9. Assay of TNF-a by ELISA
The concentrations of TNF-a in the culture medium of BV-2
microglia was determined by ELISA. Brieﬂy, medium was added
to plates that were pre-coated with rat monoclonal antibodies
against mouse TNF-a. After incubation, the plates werewashed and
Y. Chen et al. / Journal of Pharmacological Sciences 131 (2016) 131e137 133a biotinylated goat polyclonal anti-mouse TNF-a antibody was
added. Streptavidin-horseradish peroxidase conjugate and chro-
mogenic substrates were used to detect the biotinylated polyclonal
anti-mouse TNF-a antibody.
2.10. Immunocytochemistry
Translocation of the p65 subunit of NF-kB was detected by
immunocytochemistry. After treatment, BV-2 microglia were ﬁxed
with cold methanol for 30 min. Cells were rinsed three times with
PBS and then blocked with a mixture of 0.3% TritonX-100 and 3%
BSA for 90 min. The cells were incubated with a primary antibody
against p65 (Santa Cruz Biotechnology) overnight at 4 C. A sec-
ondary antibody conjugated to Alexa Fluor 488 (Molecular Probes)
was added for 90 min. The cells were then stained with Hoechst
(Molecular Probes) at 37 C for 30 min. Cell immunoﬂuorescence
was examined using an inverted ﬂuorescence microscope
(Olympus IX51, Japan).
2.11. Statistical analysis
At least three independent experiments were performed for
each treatment. Data are presented as the mean ± S.E.M. and were
analyzed by a t-test or one-way analysis of variance on ranks
(ANOVA) followed by Tukey's post-hoc test. P < 0.05 was considered
as signiﬁcantly different.
3. Results
3.1. LLDT-8 inhibited the production of NO and pro-inﬂammatory
cytokines in LPS-stimulated BV-2 microglia cells
LPS triggers inﬂammatory responses in microglia. Studies have
conﬁrmed that pro-inﬂammatory mediators, such as NO, TNF-a
and IL-1b, produced by LPS-stimulated microglia, are detrimental
to neurons (16). To investigate the anti-inﬂammatory effects of
LLDT-8, BV-2 microglia were co-treated with 100 ng/ml LPS plus
LLDT-8 at different concentrations for 24 h. NO production by
microglia, as indicated by the concentration of nitrite in the culture
medium, was signiﬁcantly increased in LPS-induced BV-2 cells
compared to control cells without LPS. LLDT-8 signiﬁcantly
inhibited NO release by BV-2 cells at concentrations ranging from
100 nM to 400 nM (Fig. 1A). To exclude the possibility that reduced
NO productionwas attributed to cell death induced by LLDT-8, MTT
assays were performed to examine the effects of LLDT-8 on cell
viability with the dose range from 50 to 400 nM. Cell viability was
not affected by LLDT-8 at the concentrations from 50 to 150 nM, but
was reduced by LLDT-8 at the dose of 400 nM (Fig. 1B). Therefore,
we used LLDT-8 within the dose range from 50 to 150 nM for the
next experiments.
The effects of LLDT-8 on iNOS, IL-1b and TNF-a mRNA expres-
sion were evaluated by qPCR in LPS-stimulated BV-2 microglia. The
results showed that the mRNA levels of iNOS, IL-1b and TNF-awere
markedly enhanced in LPS-stimulated BV-2 microglia compared to
control cells. LLDT-8 inhibited mRNA expression of iNOS, IL-1b and
TNF-a in a dose-dependent manner (Fig. 1CeE). Additionally, the
protein levels of TNF-a in LPS-treated BV-2 microglia cell cultures
were signiﬁcantly attenuated by LLDT-8 (50e150 nM) (Fig. 1F).
3.2. LLDT-8 attenuated NO production and the mRNA expression of
TNF-a, iNOS and IL-1b in LPS-stimulated primary microglia
We further conﬁrmed the anti-neuroinﬂammatory effects of
LLDT-8 on primary microglia stimulated with LPS. As shown in
Fig. 2A and B,100 ng/ml of LPS dramatically induced the productionof NO in primary microglia. LLDT-8 signiﬁcantly decreased LPS-
induced NO production in a dose-dependent manner and did not
affect the viability of primary microglia. Furthermore, LLDT-8
blunted the LPS-induced mRNA expression of TNF-a, iNOS and IL-
1b in a dose-dependent manner (Fig. 2CeE).
3.3. LLDT-8 reduced infarction and pro-inﬂammatory cytokine
expression in mice following MCAO
We investigated the effects of LLDT-8 on acute stroke outcomes
using the well-established mouse MCAO model. The animals used
and mortality for each group were described in Table 1. Compared
to vehicle, LLDT-8 administered immediately after reperfusion
signiﬁcantly reduced infarct volumes at 24 h after MCAO (Fig. 3A
and B). To determine the anti-neuroinﬂammatory effects of LLDT-8
in vivo, we measured the mRNA expression of TNF-a, iNOS and IL-
1b in themouse ischemic cortex at 24 h after reperfusion. As shown
in Fig. 3CeE, LLDT-8 remarkably attenuated the cortical tissue
mRNA expression of TNF-a, iNOS and IL-1b in the ischemic
penumbra.
3.4. LLDT-8 suppressed TLR4 expression and NF-kB activation in
LPS-stimulated BV-2 microglia cells
Toll-like receptor 4 (TLR4) is involved in microglial inﬂamma-
tion induced by LPS (17). We observed that LLDT-8 attenuated iNOS
and TLR4 protein levels in LPS-treatedmicroglia obviously at 48 h of
post-treatment (Fig. 4A). In the TLR4-mediated pro-inﬂammatory
cascade, phosphorylation of IkBa leads to the degradation of the
IkB protein and subsequent activation and nuclear translocation of
NF-kB (p65), which in turn promotes the transcription of various
inﬂammatory genes. LLDT-8 signiﬁcantly inhibited LPS-induced
phosphorylation of IkBa in BV-2 microglia (Fig. 4B). Immunoﬂuo-
rescence results further showed that translocation of NF-kB to the
nucleus was partially inhibited by LLDT-8 in LPS-stimulated BV-2
cells (Fig. 4C and D).
4. Discussion
The present study showed that LLDT-8 signiﬁcantly reduced
brain damage following acute cerebral ischemia/reperfusion injury.
LLDT-8 protected against cerebral ischemic injury possibly by
suppressing the inﬂammatory responses via the IkBa/NF-kB
cascade.
Ample evidence supports that microglia-mediated neuro-
inﬂammation induced by cerebral ischemia plays a detrimental role
(16). Over-activated microglia perform this detrimental function by
producing a large number of cytotoxic factors, including NO, TNF-a
and other proinﬂammatory cytokines (18,19). Lipopolysaccharide
(LPS) is a component of Gram-negative bacteria and is well-known
as one of the exogenous inducers of microglia-mediated neuro-
inﬂammation. The lipid A segment of LPS induces the immuno-
logical response observed in microglia. A large number of in vitro
experiments have used LPS to induce the toxic effects of microglia
(15,20,21). In LPS-stimulated BV-2 cells, enhanced NO production
contributes tomicroglia-mediated neural toxicity (20). In our study,
we observed that LPS induced NO production and the expression of
pro-inﬂammatory factors in both BV-2 microglia and primary
microglia. Compared to vehicle, LLDT-8 signiﬁcantly inhibited NO
release from BV-2 and primary microglia. Furthermore, LLDT-8
attenuated LPS-induced mRNA and protein expression of TNF-a,
iNOS and IL-1b in microglia in a dose-dependent manner.
Microglia-mediated neuroinﬂammation is thought to contribute
to the progression of neurodegenerative diseases and neurological
disorders, including MS, PD and stroke (22e24). Under certain
Fig. 1. Suppressive effects of LLDT-8 on NO production and on the expression of pro-inﬂammatory mediators in LPS-stimulated BV-2 microglia cells. (A) BV-2 cells were treated with
100 ng/ml LPS and LLDT-8 for 24 h. Production of NO was measured by Griess assay. (B) Viability was measured with MTT assay. (C, D, and E) BV-2 cells were treated with 100 ng/ml
LPS with or without LLDT-8 for 6 h and iNOS (in C), IL-1b (in D) and TNF-a (in E) mRNA expression was assessed by qPCR. (F) BV-2 microglia were treated with 100 ng/ml LPS and
LLDT-8 for 24 h (50e150 nM). The protein levels of TNF-a in the supernatant were measured by ELISA. The values are presented as the means ± the SEMs from at least 3 inde-
pendent experiments. *P < 0.05, **P < 0.01 or ***P < 0.001, compared to BV-2 treated with LPS alone; ###P < 0.001, compared to control.
Y. Chen et al. / Journal of Pharmacological Sciences 131 (2016) 131e137134circumstances, the depletion or blockade of the microglia-
mediated neuroinﬂammation prevents disease progression. More-
over, the application of anti-inﬂammatory chemicals and micro-
RNAs to prevent the acute inﬂammation response ameliorates
cerebral ischemic injury (25,26). Post-ischemic inﬂammationFig. 2. Effects of LLDT-8 on NO production and pro-inﬂammatory cytokines in primary mi
treated with LLDT-8 (50e150 nM) for 6 h. (A) The concentrations of nitrite in culture medium
assay. The mRNA expression of iNOS (in C), IL-1b (in D) and TNF-a (in E) were measured by
#P < 0.05, ##P < 0.01 or ###P < 0.001, compared to control, n ¼ 4.intervention is considered to be a promising therapeutic approach
for stroke treatment. Middle cerebral artery occlusion (MCAO) is
one of the most commonly used experimental stroke models
because the brain parenchyma perfused by MCAO is reported to be
the commonly affected area following human stroke (27).croglia stimulated with LPS. Primary microglia were stimulated by 100 ng/ml LPS and
were measured by Griess assay. (B) The cytotoxicity of LLDT-8 was determined by MTT
qPCR. *P < 0.05, **P < 0.01, ***P < 0.001, compared to microglia treated with LPS alone;
Table 1
Mortality rate.
Group Mortality (dead mice/total number)
Vehicle 1/11
0.5 mg/kg LLDT-8 1/6
1 mg/kg LLDT-8 3/13
Y. Chen et al. / Journal of Pharmacological Sciences 131 (2016) 131e137 135Therefore, the mouse MCAO stroke model was utilized in our
research. To investigate the therapeutic effect of LLDT-8 in this
stroke model, we administered LLDT-8 (i.p.) at the onset of MCAO
and analyzed the extent of histological damage at 24 h after
reperfusion with TTC staining. The TTC results showed that the
infarction area was signiﬁcantly decreased in the LLDT-8-treated
group compared to the vehicle-treated group. Based on the ﬁnd-
ings that LLDT-8 attenuated LPS-induced inﬂammation in micro-
glia, we investigated the effect of LLDT-8 on neuroinﬂammation in
themouse ischemic brain followingMCAO.We observed that LLDT-
8 attenuated the expression of the pro-inﬂammatory mediators
(TNF-a, iNOS and IL-1b) induced by MCAO.
In preclinical studies, LLDT-8 has been used as an immunosup-
pressant drug candidate to treat rheumatoid arthritis (28), auto-
immune encephalomyelitis (EAE) (8), acute hepatitis (13), graft-
versus-host disease (GVHD) (29), cardiac translation (30), and
lung ﬁbrosis (14). The mechanisms of LLDT-8 may involve blocking
IFN-g-related signaling and inﬂammatory mediators, inhibiting T
cell proliferation and activation (8,13,28). A recent study suggested
that LLDT-8 inhibited secretion of IL-1b, IL-6 and IL-21, but pro-
moted the secretion of IL-10 in the supernatants of SFMCs from
synovial ﬂuid of rheumatoid arthritis patients; furthermore, 50 nM
LLDT-8 could inhibit RANKL-induced NF-kB activation in RAW264.7
cells (31). In agreement with this study, we showed that LLDT-8
suppressed pro-inﬂammatory cytokines release.Fig. 3. Neuroprotective effects of LLDT-8 following cerebral ischemia. (A) Infarct volumes w
group; n ¼ 5 for 0.5 mg/kg LLDT-8; n ¼ 10 for 1 mg/kg LLDT-8). Mice were randomized to re
Quantitative results of infarct volumes. (C, D, and E) mRNA expression of TNF-a (in C), iNO
(n ¼ 3e8). CTX: cortex; CP: striatum; HEMI: hemisphere; CORRECT, hemisphere infarction
**P < 0.01, compared to vehicle; #P < 0.05, ##P < 0.01 compared to sham.TLR4, a crucial member of the TLR family, is expressed on the
surface of microglia. TLR4 is involved in stroke pathology. Previous
studies have shown that TLR4 knockout mice, but not TLR3 or TLR9
knock-out mice, exhibited smaller infarct volumes compared to
wild-type mice following MCAO (32). Moreover, activation of TLR4
promotes the expression of various pro-inﬂammatory cytokines via
the NF-kB cascade following MCAO (32). Thus, we investigated the
effects of LLDT-8 on the TLR4-NF-kB pathway. Under normal
physiological conditions, NF-kB is sequestered in the cytoplasm by
associating with IkBa. Stimulation of microglia by LPS leads to
phosphorylation and subsequent degradation of IkBa. Conse-
quently, NF-kB is released and then translocates to the nucleus to
facilitate the expression of a variety of target genes (33). Herein, we
observed that LLDT-8 reduced the phosphorylation of IkBa and
inhibited the translocation of the p65 subunit of NF-kB from the
cytosol to the nucleus in LPS-treated BV-2 microglia, suggesting the
TLR4-NF-kB cascade is the potential site of action through which
LLDT-8 suppresses neuroinﬂammation following stroke.
In response to cerebral ischemic injury, not only resident
microglia, astrocytes and inﬁltrating peripheral immune cells also
mediate the immune responses. As LLDT-8 possesses immuno-
suppressive effects and microglia are resident macrophages of the
central nervous system, so we focused on microglia-mediated
neuroinﬂammation in the current study. However, literatures
suggest that inﬂammation involves a cascade of cellular and mo-
lecular events leading to glial scar formation and astrogliosis
(34,35). Astrocytes are one of the key cellular components (others
such as: endothelial cells, neurons, oligodendrocytes andmicroglia)
of neurovascular unit, which are involved both in acute neuro-
inﬂammation and later tissue repair following cerebral ischemia
(36). Thus, future study is needed to clarify whether astrocytes also
participate in the anti-inﬂammatory effects of LLDT-8 on post-
stroke injury.ere evaluated by 2,3,5-triphenyltetrazolium chloride (TTC) staining (n ¼ 10 for Vehicle
ceive vehicle or LLDT-8 via intraperitoneal injection immediately after reperfusion. (B)
S (in D) and IL-1b (in E) in the cortical ischemic penumbra after 24 h of reperfusion
corrected for edema. Veh: vehicle; Ipsil: ipsilateral; Contra: contralateral. *P < 0.05 or
Fig. 4. Effects of LLDT-8 on TLR4 and NF-kB cascade in LPS-stimulated BV-2 microglia. (A) TLR4 and iNOS protein levels in BV-2 microglia cells treated by LPS with or without LLDT-
8. a-Tubulinwas used as an internal control, n¼ 4. (B) Phosphorylation of IkBawas determined by western blot analysis, n ¼ 3. (C) Effect of LLDT-8 on translocation of NF-kB (p65) in
LPS-treated BV-2 microglia was evaluated by immunocytochemistry. (D) The percentage of cells with p65 nuclear translocation was quantiﬁed, n ¼ 6. *P < 0.05, **P < 0.01 or
***P < 0.001, compared to microglia exposed to LPS alone; $$$P < 0.001, compared to BV-2 treated with LPS alone at 24 h; &&&P < 0.001, compared to BV-2 treated with LPS alone at
48 h; ##P < 0.01 or ###P < 0.001, compared to control.
Y. Chen et al. / Journal of Pharmacological Sciences 131 (2016) 131e137136In conclusion, LLDT-8 exerted anti-inﬂammatory effects and
protected against acute cerebral ischemia/reperfusion injury
possibly by blocking the IkBa/NF-kB signaling pathway.
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